FrancophonIA/ELRC3.0 huggingface dataset:
English: The clinical benefit, as measured by overall survival, was seen in all prespecified patient subgroups, including those defined by age, sex, performance status, location of primary tumour, number of organs involved and duration of metastatic disease.
Maltese: Il-benefiċċju kliniku, hekk kif imkejjel missopravivenza globali, deher f'kull sotto grupp ta' pazjenti speċifikat minn qabel, inkluż dawk magħżula skont l-età, sess, stat ta' ħila, post tat-tumur primarju, numru ta' organi involuti u t-tul talmarda metastatika.
English: PFS^ (months) Median HR (95% CI)
Maltese: PFS^ (xhur) Medjan HR (CI ta' 95%) Valur p Rata ta' rispons globali
English: Testing for proteinuria is recommended prior to start of MVASI therapy.
Maltese: Ittestjar għall-proteina fl-awrina huwa rakkomandat qabel tinbeda terapija b'MVASI.
English: The clinical benefit of bevacizumab as measured by PFS was seen in all pre-specified subgroups tested (including disease-free interval, number of metastatic sites, prior receipt of adjuvant chemotherapy and oestrogen receptor (ER) status).
Maltese: Il-benefiċċju kliniku ta' bevacizumab kif imkejjel mill-PFS intwera fis-sottogruppi taħt studju, speċifikati minn qabel, kollha (inkluż intervall mingħajr il-marda, numru ta' postijiet b'metastasi, kimoterapija awżiljarja li ngħatat minn qabel, u stat ta' riċettur għall-estroġen (ER - oestrogen receptor).
English: The safety and efficacy of the recommended dose (5 mg/kg of body weight every two weeks) in metastatic carcinoma of the colon or rectum were studied in three randomised, active-controlled clinical trials in combination with fluoropyrimidine-based first-line chemotherapy.
Maltese: Is-sigurtà u l-effikaċja tad-doża rakkomandata (5 mg/kg ta' piż tal-ġisem kull ġimagħtejn) f'karċinoma metastatika tal-kolon jew rektum ġew studjati fi 3 provi kliniċi randomised u active-controlled f'taħlita ma' kimoterapija primarja bbażata fuq fluorinopyrimidine. bevacizumab kien ikkombinat ma' żewġ korsijiet ta' kimoterapija:
English: In one clinical trial, the incidence of hypertension of grade ≥ 3 was two fold higher in patients aged > 65 years than in the younger age group (< 65 years).
Maltese: Fi prova klinika waħda, linċidenza ta' pressjoni għolja ta' grad ≥ 3 kienet ogħla d-doppju f'pazjenti b'età > 65 sena meta mqabbel mal-grupp ta' età iżgħar (< 65 sena).
English: MVASI is a medicine used for the treatment of adult patients with advanced cancer in the large bowel, i.e., in the colon or rectum.
Maltese: MVASI huwa mediċina li tintuża għall-kura ta' pazjenti adulti b'kanċer avanzat fil-musrana l-kbira, i.e. fil-kolon jew rektum.
English: • problems with the eyes (including increased production of tears),
Maltese: • problemi fl-għajnejn (inkluż żieda fil-produzzjoni ta' dmugħ),
English: MVASI, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1).
Maltese: MVASI, flimkien ma' erlotinib, huwa indikat għat-trattament primarju ta' pazjenti adulti b'kanċer talpulmun taċ-ċelluli mhux żgħar u mhux skwamużi, li ma jistgħax jitneħħa, avanzat, metastatiku jew rikorrenti b'mutazzjonijiet li jattivaw ir-Riċettur tal-Fattur tat-Tkabbir tal-Epidermide (EGFREpidermal Growth Factor Receptor) (ara sezzjoni 5.1).
English: Investigator assessment
Maltese: Valutazzjoni tal-investigatur
English: Haemorrhagea,b, Thromboembolis m (venous)a,b,
Maltese: Tromboemboliżmu (fil-vini)a,b,
English: Seventy-one patients were randomised to receive bolus 5-FU/FA or 5-FU/FA + bevacizumab (5 mg/kg every 2 weeks).
Maltese: Wieħed u sebgħin pazjent kienu randomised biex jingħataw 5-FU/FA bħala bolus jew 5-FU/FA + bevacizumab (5 mg/kg kull ġimagħtejn).
English: Overall survival results from study GOG-0240 by trial treatment Treatment comparison Other factor
Maltese: Riżultati ta' sopravivenza globali mill-istudju GOG-0240 skont il-kura tal-prova
English: One-sided log-rank p-value.
Maltese: Kanċer tal-għonq tal-utru
English: An increased incidence of post-operative bleeding or wound healing complication occurring within 60 days of major surgery was observed if the patient was being treated with bevacizumab at the time of surgery.
Maltese: Żieda fl-inċidenza ta' fsada ta' wara operazzjoni jew komplikazzjoni fil-fejqan tal-ferita li seħħew sa 60 ġurnata wara kirurġija maġġuri kienet osservata jekk il-pazjent kien ikkurat b'bevacizumab fil-ħin tal-kirurġija.
English: The overall safety profile of bevacizumab is based on data from over 5,700 patients with various malignancies, predominantly treated with bevacizumab in combination with chemotherapy in clinical trials.
Maltese: Il-profil globali ta' sigurtà ta' bevacizumab huwa bbażat fuq tagħrif minn aktar minn 5,700 pazjent b'diversi tumuri malinni kkurati primarjament b'bevacizumab flimkien ma' kimoterapija fi provi kliniċi.
English: MAHA is a haemolytic disorder which can present with red cell fragmentation, anaemia, and thrombocytopenia.
Maltese: MAHA hija disturb emolitiku li tista' tidher bi frammentazzjoni taċ-ċelluli l-ħomor, anemija u tromboċitopenija.
English: • CT arm (chemotherapy alone):
Maltese: • Grupp CT (kimoterapija waħedha):
English: • an abnormal tube-like connection or passage between the windpipe and the gullet, between internal organs and skin, between the vagina and any parts of the gut or between other tissues that are not normally connected (fistula), and are judged by your doctor to be severe,
Maltese: • konnessjoni mhux normali qisha pajp jew passaġġ bejn il-kanal tan-nifs u l-esofagu, bejn organi fuq ġewwa u l-ġilda, bejn il-vaġina u kwalunkwe parti oħra tal-musrana jew bejn tessuti oħrajn li normalment mhumiex konnessi (fistula), u huma meqjusa mit-tabib tiegħek li huma severi,
English: Τηλ.
Maltese: Sentejn.
English: Effect of bevacizumab on the pharmacokinetics of other antineoplastic agents
Maltese: TWISSIJA SPEĊJALI LI L-PRODOTT MEDIĊINALI GĦANDU JINŻAMM
English: Patients treated for persistent, recurrent, or metastatic cervical cancer with bevacizumab are at increased risk of fistulae between the vagina and any part of the GI tract (Gastrointestinal-vaginal fistulae).
Maltese: Pazjenti kkurati b'bevacizumab għall-kanċer persistenti, rikorrenti, jew metastatiku tal-għonq tal-utru huma f'riskju akbar ta' fisutli bejn il-vaġina u kwalunkwe parti tal-apparat GI (Fistuli gastro-intestinali-vaġinali).
English: Four patients had objective (partial) response, and all of these had received the 10 mg/kg dose bevacizumab; the ORR for the 10 mg/kg dose was 10%.
Maltese: Erba' pazjenti kellhom rispons oġġettiv (parzjali), u dawn kollha kienu rċievew id-doża ta' 10 mg/kg bevacizumab; l-ORR għad-doża ta' 10 mg/kg kienet ta' 10%.
English: According to the two-compartmental model, the elimination half-life is 18 days for a typical female patient and 20 days for a typical male patient.
Maltese: Skont il-mudell ta' żewġ kompartimenti, il-half-life taleliminazzjoni hija ta' 18-il ġurnata għall-pazjenta femminili tipika u ta' 20 ġurnata għall-pazjent maskili tipiku.
English: Trial E2100 efficacy results
Maltese: Riżultati tal-effikaċja fil-prova E2100
English: Table 1 provides all adverse reactions by frequency that were determined to have a causal relationship with bevacizumab through:
Maltese: Tabella 1 tipprovdi r-reazzjonijiet avversi kollha skont il-frekwenza li kienu determinati li huma kkawżati minn bevacizumab permezz ta':
English: Wound healing complicationsb,d
Maltese: Komplikazzjonijie t fil-fejqan talferitib,d,
English: Tumour-associated haemorrhage (see section 4.4)
Maltese: Perforazzjonijiet gastro-intestinali (GI) u Fistuli (ara sezzjoni 4.4)
English: The most serious adverse reactions were:
Maltese: L-aktar reazzjonijiet avversi serji kienu:
English: NAME OF THE MEDICINAL PRODUCT MVASI 25 mg/mL concentrate for solution for infusion.
Maltese: MVASI 25 mg/mL konċentrat għal soluzzjoni għall-infużjoni.
English: Ovarian failurea,b
Maltese: Anormalitajiet fil-fetua,b
English: EGFR mutation testing should be performed prior to initiation of treatment with the combination of MVASI and erlotinib.
Maltese: Ittestjar għall-mutazzjoni ta' EGFR għandu jsir qabel ma jinbeda t-trattament bil-kombinazzjoni ta' MVASI u erlotinib.
English: Post-marketing adverse reactions are included in both tables 1 and 2, where applicable.
Maltese: Reazzjonijiet avversi wara t-tqegħid fis-suq huma inklużi kemm f'tabella 1 kif ukoll f'tabella 2, fejn japplika.
English: Study JO25567 was a randomised, open-label, multi-centre phase II study conducted in Japan to evaluate the efficacy and safety of bevacizumab used in addition to erlotinib in patients with nonsquamous NSCLC with EGFR activating mutations (exon 19 deletion or exon 21 L858R mutation) who had not received prior systemic therapy for stage IIIB/IV or recurrent disease.
Maltese: II, randomised, open-label u b'aktar minn ċentru wieħed li twettaq fil-Ġappun biex jevalwa l-effikaċja u s-sigurtà ta' bevacizumab użat flimkien ma' erlotinib f'pazjenti b'NSCLC mhux skwamuż b'mutazzjonijiet li jattivaw lil EGFR (tneħħija ta' exon 19 jew mutazzjoni L858R ta' exon 21) li ma kinux irċevew terapija sistemika minn qabel għall-marda ta' stadju IIIB/IV jew rikorrenti.
English: PFS subgroup analyses depending on recurrence since last platinum therapy are summarised in table 20.
Maltese: Analiżi tas-sottogruppi ta' PFS dipendenti fuq rikorrenza mill-aħħar terapija ta' platinu huma miġbura fil-qosor f'tabella 20.
English: Venous thromboembolism: The incidence of venous thromboembolic reactions in clinical trials was similar in patients receiving bevacizumab in combination with chemotherapy compared to those receiving the control chemotherapy alone.
Maltese: L-inċidenza ta' reazzjonijiet tromboemboliċi venużi fi provi kliniċi f'pazjenti li kienu qed jirċievu bevacizumab flimkien ma' kimoterapija kienet simili għal dawk talkontroll li rċievew kimoterapija biss.
English: MVASI in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.
Maltese: Karċinoma tal-kolon jew tar-rektum li mmetastatizzat (mCRC - metastatic carcinoma of the colon or rectum)
English: Lethargy, Mucosal inflammation
Maltese: Artralġja Majalġja
English: Kaplan-Meier estimates.
Maltese: • jekk tagħmel operazzjoni.
English: Median PFS (months) HR (95% CI) p-value Response rates (for patients with measurable disease) Investigator assessment
Maltese: HR (CI ta' 95%) Valur p Rati ta' rispons (għall-pazjenti b'marda li tista' titkejjel) Valutazzjoni tal-investigatur valutazzjoni IRF
English: Non-GI Fistulae (see section 4.4)
Maltese: Pressjoni għolja (ara sezzjoni 4.4)
English: Patients may be at risk of developing infusion/hypersensitivity reactions.
Maltese: Il-pazjenti jistgħu jkunu f'riskju li jiżviluppaw reazzjonijiet relatati mal-infużjoni/ta' sensittività eċċessiva.
English: Fistulab,d, Muscular weakness, Back pain
Maltese: Axxessb,d, Ċellulite, Infezzjoni, Infezzjoni flapparat tal-awrina
English: ANNEX III LABELLING AND PACKAGE LEAFLET
Maltese: Tabella 3. Reazzjonijiet avversi rrappurtati fl-ambjent ta' wara t-tqegħid fis-suq
English: Asthenia, Fatigue, Pyrexia, Pain,
Maltese: Inċident ċerebrovaskulari, Sinkope, Ngħas,
English: Cases of osteonecrosis of the jaw (ONJ) have been reported in patients treated with bevacizumab, most of which occurred in patients who had identified risk factors for ONJ, in particular exposure to intravenous bisphosphonates and/or a history of dental disease requiring invasive dental procedures (see also section 4.4) Cases of non-mandibular osteonecrosis have been observed in bevacizumab-treated paediatric patients (see section 4.8, Paediatric population)
Maltese: Każijiet ta' osteonekrosi tax-xedaq (ONJ - osteonecrosis of the jaw) kienu rrappurtati f'pazjenti kkurati b'bevacizumab, li ħafna minnhom seħħew f'pazjenti li kellhom fatturi ta' riskju identifikati għal ONJ, speċjalment espożizzjoni għal bisphosphonates fil-vini u/jew passat ta' mard tas-snien li kien jeħtieġ proċeduri invażivi fis-snien (ara wkoll sezzjoni 4.4)
English: Low albumin and high tumour burden are generally indicative of disease severity.
Maltese: Albumina baxxa u ammont għoli ta' tumur ġeneralment huma indikattivi tas-severità tal-marda.
English: First-line treatment of non-squamous NSCLC in combination with platinum-based chemotherapy MVASI is administered in addition to platinum-based chemotherapy for up to 6 cycles of treatment followed by MVASI as a single agent until disease progression.
Maltese: Kura primarja ta' NSCLC mhux skwamuż f'kombinazzjoni ma' kimoterapija ibbażata fuq platinum MVASI jingħata flimkien ma' kimoterapija bbażata fuq platinum sa 6 ċikli ta' kura segwit minn MVASI bħala sustanża waħedha sal-progressjoni tal-marda.
English: The results for all secondary endpoints (investigator assessed EFS, and ORR and OS) were consistent in showing no improvement associated with the addition of bevacizumab to the RT/T arm compared with the RT/T arm alone.
Maltese: Irriżultati għall-punti finali sekondarji kollha (EFS evalwata mill-investigatur, u ORR u OS) kienu konsistenti għall-fatt li ma wrew l-ebda titjib assoċjat maż-żieda ta' bevacizumab mal-grupp ta' RT/T meta mqabbel mal-grupp ta' RT/T waħedhom.
English: Bevacizumab binds selectively to a protein called human vascular endothelial growth factor (VEGF), which is found on the lining of blood and lymph vessels in the body.
Maltese: Bevacizumab jingħaqad b'mod selettiv ma' proteina msejħa fattur tal-iżvilupp talendotelju vaskulari (VEGF - vascular endothelial growth factor) uman, li tinstab fuq il-kisja ta' ġewwa ta' vini/arterji tad-demm u tal-kanali tal-limfa fil-ġisem.
English: These efficacy data are consistent with the results from trial AVF2107g.
Maltese: Dan it-tagħrif dwar l-effikaċja kien konsistenti mar-riżultati osservati fil-prova AVF2107g.
English: • Hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies.
Maltese: Hamster Ovary) jew għall-antikorpi oħra umani rikombinanti jew umanizzati.
English: Posterior reversible encephalopath y syndromea,b,c, Hypertensive encephalopath yc
Maltese: Sindrome ta' enċefalopatija posterjuri riversibblia,b,ċ, Enċefalopatija ipertensivaċ
English: The safety and efficacy of bevacizumab in children less than 18 years old have not been established.
Maltese: Is-sigurtà u l-effikaċja ta' bevacizumab fi tfal ta' età inqas minn 18-il sena għadhom ma ġewx determinati s'issa.
English: Hazard ratioc p-value
Maltese: Prova kbira ta' fażi
English: Patients who have experienced a venous thromboembolic reaction may be at higher risk for a recurrence if they receive bevacizumab in combination with chemotherapy versus chemotherapy alone.
Maltese: Waqt kura b'bevacizumab, il-pazjenti jistgħu jkunu f'riskju li jiżviluppaw reazzjonijiet ta' tromboembolżmu fil-vini, inkluż emboliżmu pulmonari.
English: Hazard ratio Best overall response ratea
Maltese: Kura ta' marda rikorrenti sensittiva għall-platinu:
English: An exploratory multivariate Cox regression model using backward selection indicated that the following baseline prognostic factors were strongly associated with survival independent of treatment: gender, white blood cell count, platelets, body weight loss in the 6 months prior to trial entry, number of metastatic sites, sum of longest diameter of target lesions, Motzer score.
Maltese: Mudell esploratorju multivarjabbli ta' rigressjoni Cox bl-użu ta' selezzjoni b'lura indika li l-fatturi pronjostiċi fil-linja bażi li ġejjin kienu assoċjati b'mod qawwi mas-sopravivenza b'mod mhux dipendenti mill-kura: sess, għadd ta' ċelluli bojod fid-demm, plejtlits, telf fil-piż tal-ġisem fis-6 xhur qabel id-dħul fil-prova, numru ta' siti metastatiċi, għadd tal-itwal dijametru tal-leżjonijiet immirati, punteġġ ta' Motzer.
English: Package size blister (PVC/PVDC/alu) 50 x 1 tablet
Maltese: Mnejn jinghata Il-pakkett
English: 10x1 tablets
Maltese: Ghamla farmacewtika
English: Strength Pharmaceutical Form Route of Administration Packaging
Maltese: Daqs talpakkett
English: The active substance in Jorveza, budesonide, is a corticosteroid medicine.
Maltese: Is-sustanza attiva f'Jorveza, budesonide, hija mediċina kortikosterojde.
English: The full EPAR for Jorveza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Jorveza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Maltese: Is-sommarju tal-opinjoni tal-Kumitat għall-Prodotti Mediċinali Orfni għal Jorveza jinstab fis-sit elettroniku tal-Aġenzija: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: Other information about Jorveza
Maltese: Informazzjoni oħra dwar Jorveza
English: Jorveza contains the active substance budesonide.
Maltese: Jorveza fih is-sustanza attiva budesonide.
English: After 6 weeks, around 58% of the patients taking Jorveza (34 out of 59 patients) had reduced eosinophils and no symptoms or only minimal symptoms, whereas none of the 29 patients taking placebo had these effects.
Maltese: Wara 6 ġimgħat, madwar 58 % tal-pazjenti li kienu qed jieħdu Jorveza (34 minn 59 pazjent) kellhom esinofili mnaqqsa u l-ebda sintomu jew sintomi minimi biss, waqt li ħadd mid29 pazjent li kienu qed jieħdu l-plaċebo ma kellhom dawn l-effetti.
English: Jorveza is available as orodispersible tablets (1 mg).
Maltese: Jorveza jiġi bħala pilloli li jinħallu fil-ħalq (1 mg).
English: This is a summary of the European public assessment report (EPAR) for Jorveza.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Jorveza.
English: What are the risks associated with Jorveza?
Maltese: X'inhuma r-riskji assoċjati ma' Jorveza?
English: Jorveza was shown to be effective in one main study involving 88 adults with eosinophilic oesophagitis.
Maltese: Fi studju ewlieni wieħed li involva 88 adult b'esofagite esinofilika, intwera li Jorveza huwa effettiv.
English: Why is Jorveza approved?
Maltese: Għaliex ġie approvat Jorveza?
English: Eosinophilic oesophagitis is inflammation of the oesophagus (the food-pipe that leads from the mouth to the stomach), which causes symptoms including dysphagia (difficulty swallowing) and obstruction of the oesophagus.
Maltese: Esofagite esinofilika hija infjammazzjoni tal-esofagu (il-pajp tal-ikel li mill-ħalq iwassal għall-istonku), li jikkawża sintomi inkluż disfaġija (diffikultà biex tibla') u ostruzzjoni tal-esofagu.
English: The most common side effects with Jorveza (which may affect up to 3 in 10 people) are fungal infections in the mouth, pharynx (throat) and oesophagus.
Maltese: L-effetti sekondarji l-aktar komuni b'Jorveza (li jistgħu jaffettwaw sa 3 minn kull 10) huma infezzjonijiet fungali fil-ħalq, fil-farinġi (gerżuma) u fl-esofagu.
English: Because the number of patients with eosinophilic oesophagitis is low, the disease is considered ‘rare', and Jorveza was designated an ‘orphan medicine' (a medicine used in rare diseases) on 5 August
Maltese: Peress li n-numru ta' pazjenti li jbatu minn esofagite esinofilika huwa baxx, il-marda hija kkunsidrata ‘rari' u Jorveza ġie kklassifikat bħala ‘mediċina orfni' (mediċina li tintuża f'mard rari) fil5 ta' Awwissu 2013.
English: What measures are being taken to ensure the safe and effective use of Jorveza?
Maltese: X'miżuri qegħdin jitteħdu biex jiġi żgurat l-użu sigur u effettiv ta' Jorveza?
English: For the full list of all side effects and restrictions with Jorveza, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji kollha u r-restrizzjonijiet b'Jorveza, ara l-fuljett ta' tagħrif.
English: Jorveza is a medicine used to treat adults with eosinophilic oesophagitis.
Maltese: Dan jispjega kif l-Aġenzija vvalutat il-mediċina biex tirrakkomanda l-awtorizzazzjoni tiegħu fl-UE u l-kondizzjonijiet ta' użu tiegħu.
English: After Jorveza dissolves in the mouth, the saliva carries it to the oesophagus where it reduces the inflammation and relieves the symptoms of eosinophilic oesophagitis.
Maltese: Ilkejl ewlieni tal-effikaċja kien il-livell ta' esinofili fl-esofagu u t-titjib fis-sintomi.
English: During this time the patient should steadily swallow the saliva with the dissolved medicine.
Maltese: rakkomandata hija pillola waħda darbtejn kuljum.
English: Side effects with Jorveza are mainly the same as those of other similar medicines.
Maltese: L-effetti sekondarji b'Jorveza huma prinċipalment l-istess bħal dawk ta' mediċini simili oħra.
English: Jorveza was compared with placebo (a dummy treatment).
Maltese: Jorveza tqabbel malplaċebo (kura finta).
English: solvent: 10 ml (reconst.
Maltese: solvent: 10 ml
English: Solution 5000 IU/ml)
Maltese: IU/ml)
English: Subcutaneous or intravenous use powder: multidose vial (glass); solvent: ampoule (glass)
Maltese: IU Trab u solvent għal soluzzjoni għall injezzjoni trab: kunjett b'ħafna dożi (ħġieġ); solvent:
English: 1 vial + 1 ampoule
Maltese: kunjett + ampulla
English: Oficina D 28230 Las Rozas (Madrid) Spain
Maltese: Oficina D 28230 Las Rozas (Madrid) Spanja
English: 2700-487 Amadora Portugal
Maltese: 2700-487 Amadora
English: Sigma-Tau Industrie Farmaceutiche Riunite SpA Viale Shakespeare, 47 00144 Roma
Maltese: Sigma-Tau Industrie Farmaceutiche Riunite SpA Viale Shakespeare, 47 00144
English: LABORATOIRES ALTER 3, avenue de la Baltique, ZI de Courtaboeuf 91140 Villebon Sur Yvette France
Maltese: LABORATOIRES ALTER 3, avenue de la Baltique, ZI de Courtaboeuf 91140 Villebon Sur Yvette Franza
English: 53757 Sankt Augustin Germany
Maltese: 53757 Sankt Augustin
English: 00350 Helsinki Finland
Maltese: 00350 Helsinki Il-Finlandja
English: DEMO ABEE 21st Km Athens-Lamias National Highway 14568 Kryoneri Greece
Maltese: DEMO ABEE 21st Km Athens-Lamias National Highway 14568 Kryoneri Il-Greċja
English: Sweden Sanofi AB Box 30052
Maltese: Sanofi AB Box 30052
English: 82041 Oberhaching Germany
Maltese: 82041 Oberhaching
English: Kampenringweg 45 D-E 2803 PE GOUDA The Netherlands
Maltese: Kampenringweg 45 D-E 2803 PE GOUDA L-Olanda
English: Via Scarlatti Domenico, 31 20124 Milano Italy
Maltese: Via Scarlatti Domenico, 31 20124
English: Denmark Sandoz A/S Edvard Thomsens Vej 14 DK-2300 København S Denmark
Maltese: Id-Danimarka Sandoz A/S Edvard Thomsens Vej 14 DK-2300 København S Id-Danimarka
English: Desitin Arzneimittel GmbH Postfach 630164
Maltese: In-Norveġja Desitin Arzneimittel GmbH Postfach 630164
English: Germany IIP - Institut für industrielle Pharmazie Forschungs- und Entwicklungsgesellschaft mbH
Maltese: Il-Ġermanja IIP - Institut für industrielle Pharmazie Forschungs- und Entwicklungsgesellschaft mbH
English: Centrafarm B.V. Nieuwe Donk 3 4879 AC ETTEN LEUR The Netherlands
Maltese: Centrafarm B.V. Nieuwe Donk 3 4879 AC ETTEN LEUR L-Olanda
English: 11-15 Quai Dion Bouton 92800 Puteaux France
Maltese: Quai Dion Bouton 92800 Puteaux Franza
English: Avenida Professor Doutor Cavaco Silva, 10 E 2740-255 Porto Salvo Portugal
Maltese: Professor Doutor Cavaco Silva, 10 E 2740-255
English: Norton Healthcare Limited Ridings Point, Whistler Drive
Maltese: Ir-Renju Unit Norton Healthcare Limited Ridings Point, Whistler Drive
English: Latvia sanofi-aventis Latvia SIA Kr.Valdemara 33-8 Riga LV1010
Maltese: Il-Latvja sanofi-aventis Latvia SIA Kr.Valdemara 33-8 Riga LV1010
English: 63741 Aschaffenburg Germany
Maltese: 63741 Aschaffenburg
English: A. Juozapavičiaus g. 6/2
Maltese: Juozapavičiaus g. 6/2
English: Romania GEROT PHARMAZEUTIKA Ges.m.b.H.
Maltese: Ir-Rumanija GEROT PHARMAZEUTIKA Ges.m.b.H.
English: Luxembourg Takeda Belgium Chaussée de Gand 615 1080 Bruxelles
Maltese: Takeda Belgium Chaussée de Gand 615 1080
English: 85101 Bratislava Slovak Republic
Maltese: 85101 Bratislava
English: LT-09310 Vilnius
Maltese: LT-09310
English: Remedica Ltd Aharnon Street Limassol Industrial Estate 3056 Lemesos Cyprus
Maltese: Remedica Ltd Aharnon Street Limassol Industrial Estate 3056 Lemesos Ċipru
English: Lithuania UAB „SANOFI-AVENTIS LIETUVA“
Maltese: Il-Litwanja UAB „SANOFI-AVENTIS LIETUVA“